Research Topics
Genomes and Genes | Julian R MolinaSummaryAffiliation: Mayo Clinic Country: USA Publications
| Collaborators
|
Detail Information
Publications
Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignanciesJulian R Molina
Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
IDrugs 11:508-21. 2008..In contrast, for pralatrexate to be incorporated into the accepted treatment options for NSCLC, the drug will need to prove clear superiority to established agents...
Can gene expression profiling predict survival for patients with squamous cell carcinoma of the lung?Zhifu Sun
Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA
Mol Cancer 3:35. 2004..We also evaluated the gene markers' accuracy in segregating samples to their respective group. Functional gene networks for the significant genes were retrieved, and their association with survival was tested...- Predictors of survival from urachal cancer: a Mayo Clinic study of 49 casesJulian R Molina
Mayo Clinic and Foundation, Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer 110:2434-40. 2007..Outcome results of a long-term analysis of urachal cancer using a new staging system are presented... - Primary salivary gland-type lung cancer: spectrum of clinical presentation, histopathologic and prognostic factorsJulian R Molina
Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Cancer 110:2253-9. 2007..The clinicopathologic profiles, symptoms on presentation, and long-term outcomes of patients with ACC and MEC as an overall group have not been defined recently... - Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorshipJulian R Molina
Department of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 83:584-94. 2008.... - The Ras/Raf/MAPK pathwayJulian R Molina
Division of Medical Oncology Mayo Clinic, Rochester, MN 55905, USA
J Thorac Oncol 1:7-9. 2006 - Advances in chemotherapy of non-small cell lung cancerJulian R Molina
Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Chest 130:1211-9. 2006.... - Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial dataJulian R Molina
Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Clin Cancer Res 14:7900-8. 2008..The present studies were done to determine the effect of combining topotecan and the dual epidermal growth factor receptor/HER2 inhibitor lapatinib in tissue culture, a murine xenograft model, and a phase I clinical trial... - Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagusHongzhi Zou
Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
Int J Cancer 116:584-91. 2005..Aberrant promoter methylation appears to functionally silence SFRP gene expression in esophageal adenocarcinoma... - A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancerKeith C Bible
Division of Medical Oncology, Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
J Clin Endocrinol Metab 97:3179-84. 2012..Two patients are alive with disease 9.9 and 35 months after the registration; 13 died of disease. CONCLUSIONS: Despite preclinical in vivo activity in ATC, pazopanib has minimal single-agent clinical activity in advanced ATC... - Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002Antonio L Visbal
Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA
Ann Thorac Surg 78:209-15; discussion 215. 2004..20, 95% CI: 1.11, 1.30), particularly for patients with stage III/IV disease or adenocarcinoma. CONCLUSIONS: Male gender is confirmed to be an independent unfavorable prognostic indicator for NSCLC survival... - Effect of disrupting seven-in-absentia homolog 2 function on lung cancer cell growthAtique U Ahmed
Departments of Surgery and Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
J Natl Cancer Inst 100:1606-29. 2008..We examined whether inhibiting SIAH-2 function blocks lung cancer growth... - Aberrant methylation of the eyes absent 4 gene in ulcerative colitis-associated dysplasiaNeal K Osborn
Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Clin Gastroenterol Hepatol 4:212-8. 2006..005). CONCLUSIONS: The EYA4 gene promoter is hypermethylated commonly in sporadic and colitic neoplasia and may be associated with gene silencing. EYA4 methylation represents a candidate marker for CUC surveillance... - Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancersKeith C Bible
Mayo Clinic, Rochester, MN 55905, USA
Am J Manag Care 18:e162-7. 2012..We therefore sought to build interest in endocrine cancers, improve physician experience, and develop innovative approaches to treating patients with these neoplasms... - A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancerJulian R Molina
Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
Cancer Invest 24:382-9. 2006..6 months and 7.5 months, respectively. CONCLUSION: This second-line treatment regimen of irinotecan and docetaxel in NSCLC patients has shown activity, but can not be recommended over single-agent regimens because of significant toxicity... - Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancerJulian R Molina
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Am J Clin Oncol 29:246-51. 2006..9%. CONCLUSION: This regimen has shown similar antitumor activity to that achieved with standard therapy. Because of unacceptable toxicity and cost, we do not recommend this regimen in a palliative setting... - Do patients with schizophrenia receive state-of-the-art lung cancer therapy? A brief reportFarrah J Mateen
Department of Neurology, Mayo Clinic, Rochester, MN, USA
Psychooncology 17:721-5. 2008..Patients with schizophrenia sometimes receive substandard medical care. This study explored such disparities among lung cancer patients with underlying schizophrenia... - Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trialsNathan R Foster
Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota
Cancer 117:1262-71. 2011.... 
Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapyRobert L Foote
Endocrine Malignancies Disease Oriented Group, Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota, USA
Thyroid 21:25-30. 2011....- Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumorsPaul Haluska
Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Clin Cancer Res 13:5834-40. 2007..This phase I study was undertaken to define the maximum tolerated dose, safety, and pharmacokinetic profile of CP-751,871... - FAVL elevation in human tumors disrupts Fanconi anemia pathway signaling and promotes genomic instability and tumor growthJun Zhang
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
J Clin Invest 120:1524-34. 2010..We further believe that these data will prove useful for developing additional tools for fighting human cancer... - A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatinJulian R Molina
Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Anticancer Drugs 16:997-1002. 2005..However, the combination of BAY, VP-16 and CDBCA produces significant hematologic toxicity. Findings from this study may help to direct further studies with other inhibitors of MMPs... - The role of Pemetrexed (Alimta , LY231514) in lung cancer therapyJulian R Molina
Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
Clin Lung Cancer 5:21-7. 2003..In this review, the pharmacology and clinical activity of pemetrexed in NSCLC cancer is discussed... - Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesisMartin E Fernandez-Zapico
Gastroenterology Research Unit, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Cancer Cell 7:39-49. 2005..Thus, the discovery of prooncogenic pathways regulated by Vav1 makes it an attractive target for therapeutic intervention... - Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium studyKeith C Bible
Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
Lancet Oncol 11:962-72. 2010..We investigated the safety and efficacy of pazopanib... - Chemotherapy-induced ovarian failure: manifestations and managementJulian R Molina
Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Drug Saf 28:401-16. 2005.... - 53BP1 cooperates with p53 and functions as a haploinsufficient tumor suppressor in miceIrene M Ward
Division of Oncology Research, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
Mol Cell Biol 25:10079-86. 2005..We conclude that 53BP1 functions as a dosage-dependent caretaker that promotes genomic stability by a mechanism that preserves chromosome structure and number... - Ranibizumab combined with low-dose sorafenib for exudative age-related macular degenerationTeresa Diago
Department of Ophthalmology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 83:231-4. 2008..Randomized trials of adding sorafenib to standard therapy for patients with neovascular AMD should be considered... - Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinomaHongzhi Zou
Department of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
Cancer Epidemiol Biomarkers Prev 14:830-4. 2005.... - Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis studyRicardo S Macarenco
CIPAX, Medicina Diagnostica, Sao Jose dos Campos, Sao Paulo, Brazil
Mod Pathol 21:1168-75. 2008..Immunoexpression of epidermal growth factor receptor in salivary gland-type lung carcinomas is not related to epidermal growth factor receptor gene copy number or mutational status... - Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancerAlex A Adjei
Roswell Park Cancer Institute, Buffalo, New York 14263, USA
Clin Cancer Res 13:2684-91. 2007..To evaluate the combination of sorafenib and gefitinib in patients with advanced non-small cell lung cancer... - Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancersAlex A Adjei
Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
J Clin Oncol 26:2139-46. 2008..To assess the tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of the mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancer... - A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenesZunyan Dai
Program of Human Cancer Genetics, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH, 43210, USA
Hum Mol Genet 12:791-801. 2003..Immunohistochemistry and western blot analysis identified cIAP1 and cIAP2 as potential oncogenes in this region as both are overexpressed in multiple lung cancers with or without higher copy numbers...